## Drug Injury Watch: Testosterone Injections Or Shots Such As Depo-Testosterone Might Have Higher Risks Of Heart Attacks, Strokes, And Deaths

## New Medical Research Suggests The Safety Of A Testosterone Drug Might Depend On Its Form: Injections / Shots; Creams / Gels; Skin Patches

(Posted by Tom Lamb at <u>www.DrugInjuryWatch.com</u> on May 13, 2015)

SUMMARY: According to a large retrospective cohort medical study published online by the *JAMA Internal Medicine* journal in May 2015, we learn that short-acting testosterone injections or shots -- such as the Depo-Testosterone (testosterone cypionate) injection from Pharmacia and Upjohn Company (a division of Pfizer) -- are associated with a higher risk of cardiovascular events, hospitalizations, and deaths when compared with gels or patches.

From a May 11, 2015 news report, "Testosterone Shots: Riskier Than Gels or Patches?" -- with this sub-headline: "Spike in T levels from bolus injections may explain higher adverse outcome rates" -- published online by *MedPage Today*, we get the following summary

information and commentary about this testosterone drugs safety study:

"Different dosage forms lead to different serum testosterone levels over time -- injections result in spikes and super-normal levels -- possibly accounting for the observed risk of cardiovascular disease," [J. Bradley Layton, PhD, an epidemiologist at the University of North Carolina Chapel Hill] and colleagues wrote....

The study is well-designed and done by a reputable group, said Bradley Anawalt, MD, an endocrinologist and professor of medicine at the University of Washington Medical Center, in an email to MedPage Today. But it only included short-acting forms of injectable testosterone (testosterone cypionate, enanthate, and propionate) and not the longer-acting testosterone undecanoate which is the most common form used in Europe and which was recently approved in the U.S.

The short-acting forms of injectable testosterone are associated with higher spikes in testosterone levels, said Anawalt, who was not involved with the study.

We will continue to watch for new medical research about

testosterone drugs safety especially as regards heart attacks or myocardial infarction (MI), strokes, and cardiovascular deaths which might be caused by so-called "Low-T" testosterone therapy products such as Depo-Testosterone injections or shots.

## [Read this article in full at original source]

## Earlier articles by attorney Tom Lamb on the Side Effects Blog.

- <u>Testosterone Drugs FDA Meeting In September 2014 Reveals That The Safety Of</u>
  <u>Products Like Axiron, AndroGel, And Testim Is Uncertain Or Unknown At Present Time</u>
- AndroGel / Axiron / Testim: Heart Attacks, Strokes, And Other Cardiovascular Problems
  Will Be Subject Of FDA Advisory Panel Meeting In September 2014
- Summer 2014 Update: Testosterone "Low-T" Drugs: New FDA Safety Warnings; Recent Medical Journal Article About Heart Risks Of Injectable TRT Products
- <u>The Benefits And Risks Of Popular Testosterone Replacement Therapy For Older Men</u> <u>Are Not Fully Known</u>
- <u>Testosterone Drugs Litigation April 2014 Update: Legal & Medical Developments:</u>
  <u>AndroGel Federal Court MDL Motion Is Filed, And A "Low-T" Medical Study Is Criticized</u>

Attorney <u>Tom Lamb</u> represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments. <u>http://www.DrugInjuryWatch.com</u>